182 related articles for article (PubMed ID: 34487985)
1. Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
Matsuo K; Klar M; Mohrbacher AF; Roman LD; Wright JD
Eur J Cancer; 2021 Nov; 157():59-62. PubMed ID: 34487985
[No Abstract] [Full Text] [Related]
2. Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.
Oliveira JL; Greipp PT; Rangan A; Jatoi A; Nguyen PL
Blood Cancer J; 2022 Jan; 12(1):11. PubMed ID: 35078980
[No Abstract] [Full Text] [Related]
3. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
[TBL] [Abstract][Full Text] [Related]
4. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
Nitecki R; Melamed A; Gockley AA; Floyd J; Krause KJ; Coleman RL; Matulonis UA; Giordano SH; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2021 Jun; 161(3):653-659. PubMed ID: 33736856
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.
Ma Z; Sun XM; Lu WC; Zhao ZX; Xu ZM; Lyu JY; Zhao P; Liu LH
ESMO Open; 2021 Feb; 6(1):100033. PubMed ID: 33444891
[No Abstract] [Full Text] [Related]
6. AML and MDS associated with PARP inhibitor treatment of ovarian cancer.
Armstrong DK
Gynecol Oncol; 2023 Apr; 171():162-163. PubMed ID: 36528399
[No Abstract] [Full Text] [Related]
7. PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia.
Tinker AV
Lancet Haematol; 2021 Feb; 8(2):e97-e99. PubMed ID: 33347815
[No Abstract] [Full Text] [Related]
8. Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
O'Malley DM; Ledermann JA; Coleman RL
Gynecol Oncol; 2023 Apr; 171():164-165. PubMed ID: 36774327
[No Abstract] [Full Text] [Related]
9. Myelodysplastic Syndrome After Olaparib Treatment in Heavily Pretreated Ovarian Carcinoma.
Sari M; Saip P
Am J Ther; 2019; 26(5):e632-e633. PubMed ID: 30212381
[No Abstract] [Full Text] [Related]
10. Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
Zhu J; Tucker M; Wang E; Grossman JS; Armstrong AJ; George DJ; Zhang T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1137-e1141. PubMed ID: 28780018
[No Abstract] [Full Text] [Related]
11. A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer.
Chiusolo P; Marchetti C; Rossi M; Minnella G; Salutari V; Distefano M; Giammarco S; Metafuni E; Minucci A; Frioni F; Gasbarrino C; Colangelo M; Orteschi D; Fagotti A; Lorusso D; Pagano L; De Stefano V; Scambia G; Sica S
Am J Hematol; 2022 Nov; 97(11):E400-E403. PubMed ID: 36054600
[No Abstract] [Full Text] [Related]
12. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.
Borthakur G; Estey AE
Curr Oncol Rep; 2007 Sep; 9(5):373-7. PubMed ID: 17706165
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients.
Pitini V; Arrigo C; Aloi G; Righi M; Falduto M; Teti D
Haematologica; 2001 Oct; 86(10):E30. PubMed ID: 11602437
[No Abstract] [Full Text] [Related]
14. Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020.
Madariaga A; Bonilla L; McMullen M; Oza AM; Lheureux S
Int J Gynecol Cancer; 2020 Aug; 30(8):1256-1257. PubMed ID: 32646863
[No Abstract] [Full Text] [Related]
15. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Almanza-Huante E; Bataller A; Urrutia S; Gener-Ricos G; Briski RE; Kanagal-Shamanna R; Lu KH; Westin SN; Yap TA; Takahashi K; Ravandi F; Alvarado Y; Kadia T; Sasaki K; Kantarjian HM; Garcia-Manero G
Br J Haematol; 2023 May; 201(3):e25-e29. PubMed ID: 36951293
[No Abstract] [Full Text] [Related]
16. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
17. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
18. Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer.
Colon-Otero G; Malkasian GD; Edmonson JH
J Natl Cancer Inst; 1993 Nov; 85(22):1858-60. PubMed ID: 8230267
[No Abstract] [Full Text] [Related]
19. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL).
Garcia-Manero G; Kantarjian HM; Kornblau S; Estey E
Leukemia; 2002 Sep; 16(9):1888. PubMed ID: 12200720
[No Abstract] [Full Text] [Related]
[Next] [New Search]
